347 related articles for article (PubMed ID: 10918597)
1. The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a Burkitt's lymphoma line.
Bemark M; Neuberger MS
Oncogene; 2000 Jul; 19(30):3404-10. PubMed ID: 10918597
[TBL] [Abstract][Full Text] [Related]
2. The intron enhancer of the immunoglobulin kappa gene activates c-myc but does not induce the Burkitt-specific promoter shift.
Polack A; Strobl L; Feederle R; Schweizer M; Koch E; Eick D; Wiegand H; Bornkamm GW
Oncogene; 1991 Nov; 6(11):2033-40. PubMed ID: 1945409
[TBL] [Abstract][Full Text] [Related]
3. Variable IgH chain enhancer activity in Burkitt's lymphomas suggests an additional, direct mechanism of c-myc deregulation.
Jain VK; Judde JG; Max EE; Magrath IT
J Immunol; 1993 Jun; 150(12):5418-28. PubMed ID: 8515068
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA complementary to the E mu enhancer.
Cutrona G; Carpaneto EM; Ponzanelli A; Ulivi M; Millo E; Scarfì S; Roncella S; Benatti U; Boffa LC; Ferrarini M
Cancer Res; 2003 Oct; 63(19):6144-8. PubMed ID: 14559793
[TBL] [Abstract][Full Text] [Related]
5. Two antisense promoters in the immunoglobulin mu-switch region drive expression of c-myc in the Burkitt's lymphoma cell line BL67.
Apel TW; Mautner J; Polack A; Bornkamm GW; Eick D
Oncogene; 1992 Jul; 7(7):1267-71. PubMed ID: 1620543
[TBL] [Abstract][Full Text] [Related]
6. Antiimmunoglobulin inhibition of Burkitt's lymphoma cell proliferation and concurrent reduction of c-myc and mu heavy chain gene expression.
Arasi VE; Lieberman R; Sandlund J; Kiwanuka J; Novikovs L; Kirsch I; Hollis G; Magrath IT
Cancer Res; 1989 Jun; 49(12):3235-41. PubMed ID: 2497974
[TBL] [Abstract][Full Text] [Related]
7. Differences between Burkitt's lymphomas and mouse plasmacytomas in the immunoglobulin heavy chain/c-myc recombinations that occur in their chromosomal translocations.
Müller JR; Janz S; Potter M
Cancer Res; 1995 Nov; 55(21):5012-8. PubMed ID: 7585544
[TBL] [Abstract][Full Text] [Related]
8. Level of MYC overexpression in pediatric Burkitt's lymphoma is strongly dependent on genomic breakpoint location within the MYC locus.
Wilda M; Busch K; Klose I; Keller T; Woessmann W; Kreuder J; Harbott J; Borkhardt A
Genes Chromosomes Cancer; 2004 Oct; 41(2):178-82. PubMed ID: 15287031
[TBL] [Abstract][Full Text] [Related]
9. Absence of a paused transcription complex from the c-myc P2 promoter of the translocation chromosome in Burkitt's lymphoma cells: implication for the c-myc P1/P2 promoter shift.
Strobl LJ; Kohlhuber F; Mautner J; Polack A; Eick D
Oncogene; 1993 Jun; 8(6):1437-47. PubMed ID: 8502472
[TBL] [Abstract][Full Text] [Related]
10. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas.
Bhatia K; Huppi K; Spangler G; Siwarski D; Iyer R; Magrath I
Nat Genet; 1993 Sep; 5(1):56-61. PubMed ID: 8220424
[TBL] [Abstract][Full Text] [Related]
11. The role of immunoglobulin kappa elements in c-myc activation.
Hörtnagel K; Mautner J; Strobl LJ; Wolf DA; Christoph B; Geltinger C; Polack A
Oncogene; 1995 Apr; 10(7):1393-401. PubMed ID: 7731690
[TBL] [Abstract][Full Text] [Related]
12. Combined polymerase chain reaction methods to detect c-myc/IgH rearrangement in childhood Burkitt's lymphoma for minimal residual disease analysis.
Busch K; Borkhardt A; Wössmann W; Reiter A; Harbott J
Haematologica; 2004 Jul; 89(7):818-25. PubMed ID: 15257933
[TBL] [Abstract][Full Text] [Related]
13. Deregulation of the proto-oncogene c-myc through t(8;22) translocation in Burkitt's lymphoma.
Gerbitz A; Mautner J; Geltinger C; Hörtnagel K; Christoph B; Asenbauer H; Klobeck G; Polack A; Bornkamm GW
Oncogene; 1999 Mar; 18(9):1745-53. PubMed ID: 10208435
[TBL] [Abstract][Full Text] [Related]
14. Identification of a locus control region in the immunoglobulin heavy-chain locus that deregulates c-myc expression in plasmacytoma and Burkitt's lymphoma cells.
Madisen L; Groudine M
Genes Dev; 1994 Sep; 8(18):2212-26. PubMed ID: 7958890
[TBL] [Abstract][Full Text] [Related]
15. The mechanism of inactivation of the normal c-myc gene locus in human Burkitt lymphoma cells.
Nishikura K; Murray JM
Oncogene; 1988 May; 2(5):493-8. PubMed ID: 3131718
[TBL] [Abstract][Full Text] [Related]
16. Iron specific growth inhibition of Burkitt's lymphoma cells in vitro, associated with a decrease in translocated c-myc expression.
Habel ME; Lemieux R; Jung D
J Cell Physiol; 2005 Apr; 203(1):277-85. PubMed ID: 15468060
[TBL] [Abstract][Full Text] [Related]
17. Ongoing mutations in the N-terminal domain of c-Myc affect transactivation in Burkitt's lymphoma cell lines.
Albert T; Urlbauer B; Kohlhuber F; Hammersen B; Eick D
Oncogene; 1994 Mar; 9(3):759-63. PubMed ID: 8108117
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus nuclear antigen 2 is a transcriptional suppressor of the immunoglobulin mu gene: implications for the expression of the translocated c-myc gene in Burkitt's lymphoma cells.
Jochner N; Eick D; Zimber-Strobl U; Pawlita M; Bornkamm GW; Kempkes B
EMBO J; 1996 Jan; 15(2):375-82. PubMed ID: 8617212
[TBL] [Abstract][Full Text] [Related]
19. Expression of P0- and P3-RNA from the normal and translocated c-myc allele in Burkitt's lymphoma cells.
Eick D; Polack A; Kofler E; Lenoir GM; Rickinson AB; Bornkamm GW
Oncogene; 1990 Sep; 5(9):1397-402. PubMed ID: 2216463
[TBL] [Abstract][Full Text] [Related]
20. In a model of immunoglobulin heavy-chain (IGH)/MYC translocation, the Igh 3' regulatory region induces MYC expression at the immature stage of B cell development.
Yan Y; Park SS; Janz S; Eckhardt LA
Genes Chromosomes Cancer; 2007 Oct; 46(10):950-9. PubMed ID: 17639584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
